Sorry if someone else has picked this but my share to triple! (opppsss i mean double is)
Renovo
158p (RNVO)
Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendons and ligaments.
Our pipeline is extensive and includes four products in phase II clinical development, a further four advanced pre-clinical candidates and nine other pre-clinical candidates.
There is an estimated multi-billion dollar global market for anti-scarring drugs, and Renovo aims to be first to market with a scar prevention pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need.
Renovo plans to partner several of its products in late clinical development with companies capable of rapid global commercialisation.
reasons
Zesteem
already in phase II trials and likely to be registered in 2008 CEO says the market for this could be as much as £4 Billion a year! in the USA alone!
and they have Juvista in phase II and is being tipped as a blockbuster product bringing in revenues of £1 Billion per year.
The company has £60 million cash and has said does not need to raise any additional.
Shares mag says licensing deal should give SP a massive boost next year.(2007)
